Saeid Amiri Zadeh Fard, Haniyeh Abuei, A. Farhadi, Gholamreza Rafiei Dehbidi, F. Zare, Zahra Abbasfard, A. Behbahani
{"title":"短发夹RNA介导的人呼吸道合胞病毒基质基因沉默作为一种有效的抗病毒策略","authors":"Saeid Amiri Zadeh Fard, Haniyeh Abuei, A. Farhadi, Gholamreza Rafiei Dehbidi, F. Zare, Zahra Abbasfard, A. Behbahani","doi":"10.2217/fvl-2022-0207","DOIUrl":null,"url":null,"abstract":"Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV- M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Short hairpin RNA-mediated matrix gene silencing of human respiratory syncytial virus as a potent antiviral strategy\",\"authors\":\"Saeid Amiri Zadeh Fard, Haniyeh Abuei, A. Farhadi, Gholamreza Rafiei Dehbidi, F. Zare, Zahra Abbasfard, A. Behbahani\",\"doi\":\"10.2217/fvl-2022-0207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV- M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future.\",\"PeriodicalId\":12505,\"journal\":{\"name\":\"Future Virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/fvl-2022-0207\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fvl-2022-0207","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
Short hairpin RNA-mediated matrix gene silencing of human respiratory syncytial virus as a potent antiviral strategy
Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV- M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future.
期刊介绍:
Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.